Toolgen Inc., of Seoul, South Korea, presented data demonstrating that blocking a molecular pathway that down-regulates T-cell activity with the company's CRISPR/Cas9 gene editing platform results in increased T-cell receptor signaling in vitro and in improved antitumor activity when tested in a mouse glioblastoma tumor model.